BAUSCH + LOMB CORP (BLCO) Stock News
NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
BLCO Latest News, Press Relases and Analysis
BLCO or DHR: Which Is the Better Value Stock Right Now?
BLCO vs. DHR: Which Stock Is the Better Value Option?
Mentions: DHR
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
Mentions: BLCO.CA
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
Mentions: BLCO.CA
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
Mentions: BLCO.CA
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
Mentions: BLCO.CA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
Mentions: BLCO.CA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...
Crypto Influencer Anthony ‘Pomp’ Pompliano-Led SPAC Files for IPO
A blank-check company led by Anthony Pompliano, a cryptocurrency influencer and podcaster, has filed for an initial public offering to raise $200 million.
Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch + Lomb Announces First-Quarter 2025 Results
Mentions: BLCO.CA
CVS Health (CVS) Earnings Expected to Grow: Should You Buy?
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CVS
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
Mentions: BLCO.CA
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RVTY
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?
We recently published a list of the 10 Most Undervalued Canadian Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against other undervalued Canadian stocks according to Wall Street analysts. As February was concluding, Reuters reported that Canada’s […]